Table of Content

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.2.2 MARKETS COVERED 27
FIGURE 1 IMMUNO-ONCOLOGY ASSAYS MARKET SEGMENTATION 27
1.2.3 YEARS CONSIDERED FOR THE STUDY 28
1.3 CURRENCY 28
1.4 LIMITATIONS 28
1.5 STAKEHOLDERS 29
1.6 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.2 RESEARCH APPROACH 31
FIGURE 2 IMMUNO-ONCOLOGY ASSAYS MARKET: RESEARCH DESIGN 31
2.2.1 SECONDARY DATA 32
2.2.1.1 Key data from secondary sources 32
2.2.2 PRIMARY DATA 33
2.2.2.1 Key data from primary sources 33
2.2.2.2 Key industry insights 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 35
2.3 MARKET SIZE ESTIMATION 35
2.3.1 BOTTOM-UP APPROACH 36
FIGURE 4 IMMUNO-ONCOLOGY ASSAYS MARKET: BOTTOM-UP APPROACH 36
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 36
2.3.2 TOP-DOWN APPROACH 37
FIGURE 6 IMMUNO-ONCOLOGY ASSAYS MARKET: TOP-DOWN APPROACH 37
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 38
FIGURE 7 DATA TRIANGULATION METHODOLOGY 38
2.5 ASSUMPTIONS FOR THE STUDY 39
2.6 COVID-19 HEALTH ASSESSMENT 39
2.7 COVID-19 ECONOMIC ASSESSMENT 39
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 39
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY 40
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 41
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE IMMUNO-
ONCOLOGY ASSAYS MARKET 42
3 EXECUTIVE SUMMARY 43
FIGURE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 43
FIGURE 11 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 44
FIGURE 12 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2021 VS. 2026 (USD MILLION) 45
FIGURE 13 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 46
FIGURE 14 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 46
4 PREMIUM INSIGHTS 48
4.1 IMMUNO-ONCOLOGY ASSAYS MARKET OVERVIEW 48
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 48
4.2 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY PRODUCT & SERVICE,
2021 VS. 2026 49
FIGURE 16 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026 49
4.3 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026 49
FIGURE 17 NGS SEGMENT TO GAIN MARKET SHARE BETWEEN 2021 AND 2026 49
4.4 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY INDICATION, 2021 VS. 2026 50
FIGURE 18 LUNG CANCER SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 50
4.5 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY APPLICATION, 2021 VS. 2026 50
FIGURE 19 RESEARCH APPLICATIONS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026 50
4.6 IMMUNO-ONCOLOGY ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE IMMUNO-ONCOLOGY ASSAYS MARKET DURING THE FORECAST PERIOD 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 21 IMMUNO-ONCOLOGY ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 Rising incidence of cancer and growing adoption of targeted therapies 53
TABLE 1 GLOBAL CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025 53
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS,
2015 VS. 2018 VS. 2035 53
TABLE 3 RESEARCH FUNDING FOR NATIONAL CANCER INSTITUTE,
2016 VS. 2017 VS. 2018 (USD MILLION) 54
5.2.1.2 Increased demand for personalized medicine 54
TABLE 4 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005–2018 55
5.2.2 RESTRAINTS 55
5.2.2.1 Requirement of high capital investments and low cost-benefit ratio 55
5.2.2.2 Unfavorable regulatory and reimbursement scenario 55
5.2.2.3 High cost of immunotherapy 56
TABLE 5 COST OF KEYTRUDA, BY COUNTRY (2018) 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Emerging markets offer lucrative opportunities 57
5.2.3.2 Growing significance of companion diagnostics 58
5.2.4 CHALLENGES 58
5.2.4.1 Low awareness of cancer immunotherapy 58
5.3 IMPACT OF COVID-19 ON THE IMMUNO-ONCOLOGY ASSAYS MARKET 59
5.4 PRICING ANALYSIS 60
TABLE 6 PRICE OF IMMUNO-ONCOLOGY ASSAYS (2021) 60
5.5 PATENT ANALYSIS 60
5.6 TRADE ANALYSIS 61
5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 61
TABLE 7 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION) 61
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (TONS) 61
5.7 VALUE CHAIN ANALYSIS 61
FIGURE 22 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE 62
5.8 SUPPLY CHAIN ANALYSIS 62
FIGURE 23 DISTRIBUTION?A STRATEGY PREFERRED BY PROMINENT COMPANIES 63
5.9 ECOSYSTEM ANALYSIS OF THE IMMUNO-ONCOLOGY ASSAYS MARKET 64
FIGURE 24 IMMUNO-ONCOLOGY ASSAYS MARKET: ECOSYSTEM ANALYSIS 64
5.10 PORTER’S FIVE FORCES ANALYSIS 64
TABLE 9 IMMUNO-ONCOLOGY ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS 64
5.10.1 THREAT OF NEW ENTRANTS 65
5.10.2 THREAT OF SUBSTITUTES 65
5.10.3 BARGAINING POWER OF BUYERS 65
5.10.4 BARGAINING POWER OF SUPPLIERS 65
5.10.5 DEGREE OF COMPETITION 65
5.11 PESTLE ANALYSIS 66
5.12 REGULATORY LANDSCAPE 67
5.12.1 NORTH AMERICA 67
5.12.1.1 US 67
5.12.1.2 CANADA 67
5.12.2 EUROPE 67
5.12.3 ASIA PACIFIC 67
5.12.3.1 JAPAN 67
5.12.3.2 INDIA 68
5.12.4 LATIN AMERICA 68
5.12.4.1 BRAZIL 68
5.12.4.2 MEXICO 68
5.12.5 MIDDLE EAST 68
5.12.6 AFRICA 69
5.13 TECHNOLOGY ANALYSIS 69
5.14 YC-YCC SHIFT 70
5.14.1 YC-YCC SHIFT FOR THE IMMUNO-ONCOLOGY ASSAYS MARKET 70
6 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE 71
6.1 INTRODUCTION 72
TABLE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 72
6.2 CONSUMABLES 72
6.2.1 RECURRENT PURCHASE OF KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH 72
TABLE 11 KEY PRODUCTS IN THE CONSUMABLES MARKET 73
TABLE 12 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2019–2026 (USD MILLION) 74
6.3 INSTRUMENTS 74
6.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED PRODUCTS TO SUPPORT MARKET GROWTH 74
TABLE 13 KEY PRODUCTS IN THE INSTRUMENTS MARKET 75
TABLE 14 IMMUNO-ONCOLOGY ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION) 75
6.4 SOFTWARE & SERVICES 75
6.4.1 INCREASING NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS TO SUPPORT MARKET GROWTH 75
TABLE 15 IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE & SERVICES,
BY REGION, 2019–2026 (USD MILLION) 76
7 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY 77
7.1 INTRODUCTION 78
TABLE 16 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 78
7.2 POLYMERASE CHAIN REACTION 78
7.2.1 EMERGENCE OF ADVANCED PCR TECHNOLOGIES TO SUPPORT MARKET GROWTH 78
TABLE 17 IMMUNO-ONCOLOGY ASSAYS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2019–2026 (USD MILLION) 79
7.3 IMMUNOASSAY 80
7.3.1 IMMUNOASSAYS HAVE THE POTENTIAL TO REDUCE CANCER MORTALITY RATE BY FACILITATING THE DIAGNOSIS OF CANCER AT AN EARLY STAGE 80
TABLE 18 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY, BY REGION, 2019–2026 (USD MILLION) 81
?
7.4 NEXT-GENERATION SEQUENCING 81
7.4.1 NGS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 81
TABLE 19 IMMUNO-ONCOLOGY ASSAYS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2019–2026 (USD MILLION) 82
7.5 IN SITU HYBRIDIZATION 82
7.5.1 HIGH DEMAND FOR IN SITU HYBRIDIZATION IN THE DIAGNOSIS OF SMALL TUMORS TO DRIVE MARKET GROWTH 82
TABLE 20 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IN SITU HYBRIDIZATION,
BY REGION, 2019–2026 (USD MILLION) 83
7.6 FLOW CYTOMETRY 83
7.6.1 GROWING INCIDENCE & PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH 83
TABLE 21 IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2019–2026 (USD MILLION) 84
8 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION 85
8.1 INTRODUCTION 86
TABLE 22 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 86
8.2 LUNG CANCER 86
8.2.1 INCREASING RESEARCH ON LUNG CANCER BIOMARKERS TO DRIVE MARKET GROWTH 86
TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2018 VS. 2025 87
TABLE 24 IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION) 87
8.3 BREAST CANCER 88
8.3.1 INCREASING GOVERNMENT FUNDING FOR BREAST CANCER
RESEARCH TO DRIVE MARKET GROWTH 88
TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2018 VS. 2025 88
TABLE 26 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION) 89
8.4 COLORECTAL CANCER 89
8.4.1 INCREASING PREVALENCE OF COLORECTAL CANCER TO
PROPEL MARKET GROWTH 89
FIGURE 25 COLORECTAL CANCER INCIDENCE RATE IN KEY COUNTRIES (2018) 90
TABLE 27 IMMUNO-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER,
BY REGION, 2019–2026 (USD MILLION) 90
8.5 BLADDER CANCER 90
8.5.1 BLADDER CANCER SEGMENT TO WITNESS SLOWER GROWTH OWING TO THE LIMITED ADOPTION OF IMMUNO-ONCOLOGY ASSAYS 90
TABLE 28 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY REGION, 2019–2026 (USD MILLION) 91
8.6 MELANOMA 91
8.6.1 GROWING INCIDENCE OF MELANOMA TO DRIVE THE DEMAND FOR IMMUNO-ONCOLOGY ASSAYS 91
TABLE 29 IMMUNO-ONCOLOGY ASSAYS MARKET FOR MELANOMA, BY REGION,
2019–2026 (USD MILLION) 92
8.7 OTHER CANCERS 92
TABLE 30 GLOBAL CANCER INCIDENCE, 2020 92
TABLE 31 IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS,
BY REGION, 2019–2026 (USD MILLION) 93
9 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION 94
9.1 INTRODUCTION 95
TABLE 32 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 95
9.2 RESEARCH APPLICATIONS 95
9.2.1 RISING PROMINENCE OF BIOMARKER-BASED DRUG DEVELOPMENT TO DRIVE THE RESEARCH APPLICATIONS MARKET 95
TABLE 33 IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2019–2026 (USD MILLION) 96
9.3 CLINICAL DIAGNOSTICS 96
9.3.1 BENEFITS OF IMMUNO-ONCOLOGY ASSAYS ARE DRIVING THEIR ADOPTION IN CLINICAL DIAGNOSTICS 96
TABLE 34 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CLINICAL DIAGNOSTICS,
BY REGION, 2019–2026 (USD MILLION) 97
10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION 98
10.1 INTRODUCTION 99
TABLE 35 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION,
2019–2026 (USD MILLION) 99
10.2 NORTH AMERICA 99
FIGURE 26 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 100
FIGURE 27 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT 101
TABLE 36 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 37 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 102
TABLE 38 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 102
TABLE 39 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 102
TABLE 40 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 103
10.2.1 US 103
10.2.1.1 The US dominates the North American immuno-
oncology assays market 103
TABLE 41 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 104
TABLE 42 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 104
TABLE 43 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 104
TABLE 44 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 105
TABLE 45 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 105
10.2.2 CANADA 105
10.2.2.1 Increasing government initiatives focused on promoting research to support market growth 105
TABLE 46 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 106
TABLE 47 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 107
TABLE 48 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 107
TABLE 49 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 108
TABLE 50 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 108
10.3 EUROPE 108
FIGURE 28 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 109
TABLE 51 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 109
TABLE 52 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 110
TABLE 53 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 110
TABLE 54 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 110
TABLE 55 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 111
10.3.1 GERMANY 111
10.3.1.1 Germany to dominate the European immuno-oncology assays market during the forecast period 111
TABLE 56 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 112
TABLE 57 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 112
TABLE 58 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 112
TABLE 59 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 113
TABLE 60 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 113
10.3.2 ITALY 113
10.3.2.1 Increasing life science R&D in Italy to drive market growth 113
TABLE 61 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 114
TABLE 62 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 114
TABLE 63 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 115
TABLE 64 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 115
TABLE 65 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 115
10.3.3 FRANCE 116
10.3.3.1 Increasing government funding for research to support market growth in France 116
TABLE 66 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 116
TABLE 67 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 117
TABLE 68 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 117
TABLE 69 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 117
TABLE 70 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 118
10.3.4 UK 118
10.3.4.1 Growth in the country’s life science industry and increasing focus on research to propel market growth 118
TABLE 71 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 119
TABLE 72 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 119
TABLE 73 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 119
TABLE 74 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 120
10.3.5 SPAIN 120
10.3.5.1 Increasing focus on the advancement of personalized medicine in Spain to drive market growth 120
TABLE 75 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 121
TABLE 76 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 121
TABLE 77 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 122
TABLE 78 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 122
10.3.6 REST OF EUROPE 122
TABLE 79 ROE: CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040 123
TABLE 80 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040 123
TABLE 81 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 123
TABLE 82 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 124
TABLE 83 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 124
TABLE 84 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 124
10.4 ASIA PACIFIC 125
FIGURE 29 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 125
FIGURE 30 ASIA PACIFIC: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT 126
TABLE 85 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
TABLE 86 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 127
TABLE 87 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 127
TABLE 88 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 127
TABLE 89 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 128
10.4.1 CHINA 128
10.4.1.1 China accounts for the largest share of the APAC market 128
TABLE 90 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 129
TABLE 91 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 129
TABLE 92 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 130
TABLE 93 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 130
TABLE 94 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 130
10.4.2 JAPAN 131
10.4.2.1 Research initiatives toward the development of precision medicine are supporting market growth in Japan 131
TABLE 95 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 131
TABLE 96 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 132
TABLE 97 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 132
TABLE 98 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 132
TABLE 99 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 133
10.4.3 INDIA 133
10.4.3.1 Increased demand for early cancer diagnosis to support market growth in India 133
TABLE 100 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 134
TABLE 101 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 134
TABLE 102 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 134
TABLE 103 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 135
TABLE 104 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 135
10.4.4 REST OF ASIA PACIFIC 135
TABLE 105 ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040 136
TABLE 106 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 136
TABLE 107 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 137
TABLE 108 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 137
TABLE 109 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 137
10.5 LATIN AMERICA 138
10.5.1 GROWING CONTRACT RESEARCH AND MANUFACTURING ACTIVITIES IN THE REGION TO SUPPORT MARKET GROWTH 138
TABLE 110 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 138
TABLE 111 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 139
TABLE 112 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 139
TABLE 113 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 139
10.6 MIDDLE EAST & AFRICA 140
10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE THE MARKET GROWTH 140
TABLE 114 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET,
BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 140
TABLE 115 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 141
TABLE 116 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 141
TABLE 117 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 141
11 COMPETITIVE LANDSCAPE 142
11.1 OVERVIEW 142
11.2 KEY PLAYER STRATEGIES 142
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 143
FIGURE 31 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET 143
11.4 MARKET SHARE ANALYSIS 143
FIGURE 32 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER (2020) 143
11.5 COMPANY EVALUATION QUADRANT 144
11.5.1 LIST OF EVALUATED VENDORS 145
11.5.2 STARS 145
11.5.3 EMERGING LEADERS 145
11.5.4 PERVASIVE PLAYERS 145
11.5.5 PARTICIPANTS 145
FIGURE 33 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 146
11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020) 146
11.6.1 PROGRESSIVE COMPANIES 146
11.6.2 STARTING BLOCKS 147
11.6.3 RESPONSIVE COMPANIES 147
11.6.4 DYNAMIC COMPANIES 147
FIGURE 34 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020 147
11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS 148
FIGURE 35 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET 148
11.8 COMPETITIVE SCENARIO 148
11.8.1 MARKET EVALUATION FRAMEWORK, 2018–2020 148
11.8.2 PRODUCT LAUNCHES & REGULATORY APPROVALS 149
TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS 149
11.8.3 DEALS 149
TABLE 119 KEY DEALS 149
11.8.4 OTHER DEVELOPMENTS 150
TABLE 120 OTHER KEY DEVELOPMENTS 150
12 COMPANY PROFILES 151
12.1 KEY PLAYERS 151
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1.1 THERMO FISHER SCIENTIFIC, INC. 151
TABLE 121 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 151
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 152
12.1.2 F. HOFFMANN-LA ROCHE LTD. 158
TABLE 122 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 158
FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 159
12.1.3 ILLUMINA, INC. 162
TABLE 123 ILLUMINA, INC.: BUSINESS OVERVIEW 162
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020) 163
12.1.4 MERCK MILLIPORE 166
TABLE 124 MERCK MILLIPORE: BUSINESS OVERVIEW 166
FIGURE 39 MERCK MILLIPORE: COMPANY SNAPSHOT (2020) 166
12.1.5 AGILENT TECHNOLOGIES, INC. 169
TABLE 125 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 169
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020) 169
12.1.6 ABBOTT LABORATORIES, INC. 173
TABLE 126 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW 173
FIGURE 41 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 174
12.1.7 SARTORIUS AG 175
TABLE 127 SARTORIUS AG: BUSINESS OVERVIEW 175
FIGURE 42 SARTORIUS AG: COMPANY SNAPSHOT (2020) 175
12.1.8 NANOSTRING TECHNOLOGIES, INC. 178
TABLE 128 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW 178
FIGURE 43 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020) 178
12.1.9 HTG MOLECULAR DIAGNOSTICS, INC. 181
TABLE 129 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW 181
FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2019) 182
12.1.10 PERKINELMER, INC. 185
TABLE 130 PERKINELMER, INC.: BUSINESS OVERVIEW 185
FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2020) 186
12.1.11 QIAGEN N.V. 187
TABLE 131 QIAGEN N.V.: BUSINESS OVERVIEW 187
FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2019) 187
12.2 OTHER PLAYERS 190
12.2.1 BIOM?RIEUX SA 190
TABLE 132 BIOM?RIEUX SA: BUSINESS OVERVIEW 190
FIGURE 47 BIOM?RIEUX SA: COMPANY SNAPSHOT (2020) 191
12.2.2 MYRIAD GENETICS, INC. 192
TABLE 133 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW 192
FIGURE 48 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2019) 192
12.2.3 GUARDANT HEALTH, INC. 195
TABLE 134 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW 195
FIGURE 49 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2019) 195
12.2.4 BIO-RAD LABORATORIES, INC. 197
12.2.5 CHARLES RIVER LABORATORIES, INC. 198
12.2.6 SEEGENE INC. 200
TABLE 135 SEEGENE INC.: BUSINESS OVERVIEW 200
12.2.7 MESO SCALE DIAGNOSTICS, LLC. 201
TABLE 136 MESO SCALE DIAGNOSTICS, LLC.: BUSINESS OVERVIEW 201
12.2.8 OLINK 202
12.2.9 ASURAGEN, INC. 202
12.2.10 INVIVOSCRIBE, INC. 204
12.2.11 CREATIVE BIOLABS 205
12.2.12 REACHBIO LLC 206
12.2.13 NMI TECHNOLOGIETRANSFER GMBH 207
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies
?
13 APPENDIX 208
13.1 INSIGHTS FROM INDUSTRY EXPERTS 208
13.2 DISCUSSION GUIDE 209
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 211
13.4 AVAILABLE CUSTOMIZATIONS 213
13.5 RELATED REPORTS 213
13.6 AUTHOR DETAILS 214